Pro Health Tips
Thursday, 21 May 2020
Durvalumab Combo Improved Survival in Mesothelioma
Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination of Durvalumab with pemetrexed and cisplatin could advance to a randomized phase 3 study.
from Medindia Health News https://ift.tt/2ARP57L
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Phase 2 trial PrE0505 selected for oral presentation at ASCO 2020; data signals the combination of Durvalumab with pemetrexed and cisplatin could advance to a randomized phase 3 study.
No comments:
Post a Comment